

## AMPHOTERICIN-B: A DRUG APPROACH IN FUNGAL TREATMENT

Ashok Kumar Sharma<sup>1\*</sup>, Pushpendra Singh Naruka<sup>2</sup>, Shankar Lal Soni<sup>1</sup>,  
Vani Madaan<sup>1</sup>, Vandana Sharma<sup>3</sup>, Mukesh Sharma<sup>4</sup>

<sup>1</sup>Research Scholar, Faculty of Pharmacy, B. N. University, Udaipur, Rajasthan

<sup>2</sup>Asso. Professor, Faculty of Pharmacy, B. N. University, Udaipur, Rajasthan

<sup>3</sup>Principal, Arya College of Pharmacy, Jaipur, Rajasthan

<sup>4</sup>Professor, Arya College of Pharmacy, Jaipur, Rajasthan

Received: 14-12-2021 / Revised: 06-01-2022 / Accepted: 07-02-2022

Corresponding author: Ashok Kumar Sharma

Conflict of interest: Nil

### Abstract

Amphotericin B (AmB) is a polyene macrolide class of antifungal agent and it is the drug of choice for systemic fungal infection, but unfortunately, oral bioavailability of this drug is negligible due to its low aqueous solubility. Amphotericin-B is a potent and effective antifungal medication used for serious fungal infections. It is used to treat aspergillosis, blastomycosis, candidiasis and cryptococcosis and many other fungal infection. It is typically given by injection into a vein, now a day's it used topically like-cream and gel. Common side effects fever, chills, headaches and Nephrotoxicity (kidney problem). Amphotericin-B act as forming pores in cell membrane that causes leakage of monovalent ions and subsequent fungal cell death.

**Keyword:** Antifungal, polyene macrolide, blastomycosis, bioavailability, leishmaniasis, aspergillosis, injection

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

### INTRODUCTION

Fungi are large organisms that typically survive on dead rotting animal and plant matter. They are found mostly in soil, an object contaminated with soil, on plants and animals skin, and that they may additionally be airborne. Fungi may exist as yeasts or molds and will alternate between the two forms, looking on environmental conditions. Yeasts are simple cells, 3 to 5 micrometres (0.0001 to 0.0002inch) in the whole diameter. Molds include filamentous of branching structures (called hyphae), 2 to 10 micrometres in diameter, that are formed of several cells lying end to finish.[1-6] Fungal diseases in humans are called

mycoses; they include such disorders as histoplasmosis, coccidioidomycosis, blastomycosis, Mucormycosis.

#### Transmission

Fungi cells always reproduced by spreading single celled spores. The structure of a fungus is long and cylindrical, with small filaments branching from the body. Many fungal infections develop on the upper most layers of the skin, and some reached and spread in the deeper layers. Inhaled yeast or mold spores can sometimes lead to fungal infections, like pneumonia, or infections throughout the body. These also are called systemic infections.[7-12]

#### Antifungal Drugs

The most frequently used polyene macrolides are amphotericin-B and nystatin. These drugs act by binding to ergosterol in cell membranes increasing permeability, disrupting metabolism and causing death of cell. Amphotericin-B is a broad spectrum of activity against most species of *Candida* and *Aspergillus*. Amphotericin-B has been available since last four decade and exists in many type of formulations; however, because the oral bioavailability of amphotericin-B is less than 5%. So oral formulations are difficult to made. Intravenous formulations of amphotericin-B are used in the management of systemic fungal infections. [14-18]

### Allylamines

The allylamine terbinafine inhibits squalene epoxidase, which acts in ergosterol depletion, membrane disruption and death of fungus cell.<sup>19</sup> Terbinafine has activity against dermatophytes, low activity against *Aspergillus* spp. and other filamentous fungi but limited activity against *Candida* spp. The drug is registered for topical and oral treatment of cutaneous and nails dermatophyte infections, because terbinafine is lipophilic and keratinophilic,

it accumulates in sebum, hair and nails. Terbinafine has been used alone or together with amphotericin-B or azoles for the treatment of invasive fungal infections.[19-22]

### CHEMISTRY

Amphotericin-B is crystalline in bright yellow color having solid state. It show crystalline solid at room temperature that show physical characteristic of the drug. Amphotericin-B is water insoluble potent antifungal drug which belongs to the amino benzimidazole family drug. [24]

### Amphotericin-B

Molecular weight: 924.09g/mol

Molecular Formula: C<sub>47</sub>H<sub>73</sub>NO<sub>17</sub>

Melting point: 170°C

Boiling point: 100°C


Density: 0.9g/cm<sup>3</sup>

Flash Point: 163°C

Solubility: Amphotericin-B is bright yellow crystalline powder soluble in DMSO, Lipids and insoluble in water.

Storage: Store at well closed amber colored container.

### CHEMICAL STRUCTURE



**CHEMICAL PROPERTIES**

Appearance- Amphotericin-B is solid crystalline powder in nature with bright yellow colour.

Solubility- Amphotericin-B is slightly soluble in DMSO (di-methyl-sulfoxide), but is insoluble in water.[5-9]

**PHARMACODYNAMICS/MECHANISM OF ACTION**

Amphotericin-B is an antifungal medication used for serious fungal infections and leishmaniasis. It is accustomed to treat aspergillosis, blastomycosis, candidiasis and cryptococcosis. It is typically given by injection into a vein. Common side effects are fever, chills, headaches and kidney problem. [25-28]

**Mechanism of action:**

polyene antifungals, amphotericin B associates with ergosterol, the main component of fungal cell membranes, forming a transmembrane channel that acts as a monovalent ion (K<sup>+</sup>, Na<sup>+</sup>, H<sup>+</sup> and Cl<sup>-</sup>) leakage, which is the primary effect resulting in fungal cell death. Recently, however, researchers found evidence that pore formation isn't necessarily linked to cell death. The particular mechanism of action is also more complex and multifaceted. [29-32]

**Pharmacokinetics:**

Amphotericin B is very poorly absorbed when given orally, and this route is employed just for treating fungal infections of the upper alimentary canal. It is often used topically for local infection on skin. For systemic infections it is generally administered by slow injection complexed with liposomes or other lipid-containing preparations. This improves the pharmacokinetics and reduces the considerable burden of side effects. Amphotericin B is extremely highly

protein bound. It penetrates tissues and membranes (such as the blood-brain barrier) poorly, although it is found in high concentrations in inflammatory exudates and should cross the blood-brain barrier more readily when the meninges are inflamed, and intravenous Amphotericin-B is employed with flucytosine to treat cryptococcal meningitis. It is excreted very slowly via the kidney, traces being found within the urine for two months or more after administration has ceased.

**Medicinal uses:-****Antifungal Activity-**

Amphotericin B is an antifungal drug used to treat fungal infections in neutropenic patients, cryptococcal meningitis in HIV infection, fungal infections, and leishmaniasis.

**Black fungus treatment-**

Amphotericin-B is widely used to treat post-covid symptoms black fungus (Mucormycosis) by inhibiting the synthesis of ergosterol, the most important component of fungal cell membranes.[18-21]

**Side effects**

Amphotericin-B has some of the following common side effects.

- Fever and chills.
- increased or decreased urination.
- irregular heartbeat.
- muscle cramps or pain.
- nausea.
- pain at the place of injection.
- unusual tiredness or weakness.
- vomiting.

**Adverse drug reactions:**

The adverse reactions most commonly observed are:

General (body as a whole): fever, malaise, weight loss.

hypotension tachypnea, anorexia; nausea; vomiting; diarrhea

Hematologic: normochromic anemia, normocytic anemia, Local: pain at the injection site, generalized pain, including muscle and joint pains.

**Acknowledgement**

Many-Many thanks to all of the Faculty members and researchers who informed and feedback that made this chapter possible and especially for Dr. Pushpendra Singh Naruka (Associate Professor, Faculty of Pharmacy, B.N. University) his assistance with the preparation. Special appreciation goes to Dr. Y S Sarangdevot (Dean Faculty of Pharmacy, B.N. University) for providing such academic environment and publication motivational environment.

## REFERENCES

1. Sehgal, Mukul; Ladd, Hugh J.; Totapally, Balangandhar (2020-12-01)
2. O'Brien, Deirdre J.; Gould, Ian M. (August 2013). "Maximizing the impact of antimicrobial stewardship". *Current Opinion in Infectious Diseases*. **26** (4): 352–58.
3. Alberti K.P., King L.A., Burny M.E., Ilunga B.K., Grais R.F. Reactive vaccination as an effective tool for measles outbreak control in measles mortality reduction settings, Democratic Republic of Congo, 2005–2006. *International Health*. 2010;2:65–68.
4. Anderson J.D., Bonner M., Scheifele D.W., Schneider B.C. Lack of nosocomial spread of Varicella in a pediatric hospital with negative pressure ventilated patient rooms. *Infection Control*. 1985;6:120–121.
5. Arvelo W., Sosa S.M., Juliao P., Lopez M.R., Estevez A., Lopez B., Morales-Betoulle M.E., Gonzalez M., Gregoricus N.A., Hall A.J., Vinje J., Parashar U., Lindblade K.A. Norovirus outbreak of probable waterborne transmission with high attack rate in a Guatemalan resort. *Journal of Clinical Virology* 2012;55:8–11.
6. Asiedu-Bekoe F., Adu D.A., Offei A. Mass oseltamivir prophylaxis halts pandemic influenza A H1N1 2009 outbreak in a secondary school in Ashanti Region, Ghana. *Ghana Medical Journal*. 2012;46:219–224.
7. Bootsma M.C., Ferguson N.M. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104:7588–7593.
8. Bannister B.A., Begg N.T., Gillespie S.H., editors. *Structure and classification of pathogens*. 2nd edn. Blackwell Science Ltd; Oxford, UK: 1996. pp. 23–34.
9. Benenson A.S., editor. *Control of Communicable Diseases Manual*. 16th edn. American Public Health Association; Washington, DC: 1995.
10. Luby S.P. Effect of handwashing on child health: A randomised controlled trial. *Lancet*. 2005;366:225–233.
11. Engleberg N.C., DiRita V., Dermody T.S. Lippincott Williams and Wilkins; Baltimore, MD: 2007. *Schaechter's Mechanisms of Microbial Disease*.
12. Detels R., McEwen J., Beaglehole J., Tanaka H., editors. *Oxford Textbook of Public Health*. 4th edn. Oxford University Press; Oxford, UK: 2002.
13. S. M. Pimentel-Elardo, S. Kozytska, T. S. Bugni, C. M. Ireland, H. Moll, and U. Hentschel, "Anti-parasitic compounds from streptomyces sp. strains isolated from mediterranean sponges," *Marine Drugs*, vol. 8, no. 2, pp. 373–380, 2010.
14. R. H. Dahal, D. S. Shim, and J. Kim, "Development of actinobacterial resources for functional cosmetics," *Journal of Cosmetic Dermatology*, vol. 16, no. 2, pp. 243–252, 2017.
15. S. H. Gillespie, "Evolution of drug resistance in mycobacterium tuberculosis: clinical and molecular perspective," *Antimicrobial Agents and Chemotherapy*, vol. 46, no. 2, pp. 267–274, 2002.
16. E. A. Eady, M. Gloor, and J. J. Leyden, "Propionibacterium acnes resistance: a worldwide problem," *Dermatology*, vol. 206, no. 1, pp. 54–56, 2003.

17. L. A. Dever and T. S. Dermody, "Mechanisms of bacterial resistance to antibiotics," *Archives of internal medicine*, vol. 151, no. 5, pp. 886–895, 1991.
18. Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. *F1000Prime Rep*. 2014;6.
19. Fisher MC, Henk DA, Briggs CJ, et al. Emerging fungal threats to animal, plant and ecosystem health. *Nature*. 2012;484:186–194.
20. Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001–2010. *Emerg Infect Dis*. 2014;20:1149–1155.
21. Cornely OA, Bassetti M, Calandra T, et al. ESCMID\* guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect*. 2012;18(Suppl 7):19–37.
22. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med*. 2002;347:408–415.
23. Garber G. An overview of fungal infections. *Drugs* 2001; 61 Suppl. 1: 1–12.
24. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. *Bone Marrow Transplant* 1997; 19: 801–8.
25. Tumbarello M, Tacconelli E, Pagano L, et al. Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. *J Infect* 1997; 34: 55–60.
26. Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. *J Infect* 1996; 33: 23–32.
27. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? *Biochim Biophys Acta* 1986; 864: 257–304.
28. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. *Rev Infect Dis* 1990; 12: 308–29.
29. Schafer-Korting M, Blechschmidt J, Korting HC. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. *Mycoses* 1996; 39: 329–39.
30. Ryder NS. The mechanism of action of terbinafine. *Clin Exp Dermatol* 1989; 14: 98–100.
31. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. *Drugs* 1992; 43: 259–84.
32. Harari S, Schiraldi G, de Juli E, et al. Relapsing *Aspergillus* bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent [letter]. *Chest* 1997; 111: 835–6.